To Get More Information on Orthobiologics Market - Request Sample Report
The Orthobiologics Market was valued USD 7.15 billion in 2023 anticipated to grow USD 11.59 billion by 2032 with compound annual growth rate of 5.55% over the forecast period 2024-2032.
Orthobiologic drugs are advancing to include growth factors as a piece of the market. These biocompatible materials stimulate tissue regeneration and pain relief, setting a new course away from traditional surgical treatment. Primary market drivers include the aging population, who are more prone to osteoarthritis. Other factors, including increasing obesity rates and more accidents as well as a heightened understanding of sophisticated treatments on the orthobiologics market are driving demand higher.
High incidence of bone diseases including tumors and infections (leading to prolonged recovery) is a major factor driving the growth of orthobiologics market. These products helped with treating a variety of traumas, bone lesions and fractures as well. They are favored for the treatment of bone defects due to their efficacy as the preferred treatment option. Furthermore, the increasing application of stem cell-based allografts in orthopedic procedures is also boosting orthobiologics market growth.
A fast-growing area of regenerative medicine, orthobiologics provides non-surgical alternatives for patients with acute orthopedic complaints and chronic degenerative processes. These bioactive products use growth factors to relieve pain, promote the healing process of tissues and restore function. Given varied mechanisms of action and promising results in muscle, joint and soft tissue injuries, orthobiologics have been frequently the focus on much enterprise interest.
The result for patients is further access to its bone regeneration tech, which was marked as a big win in OssDsign's favor. Premier Inc., a leading health care alliance serving approximately 4,350 U.S. hospitals and more than 300,000 other providers has executed a new three-year group purchasing agreement with the company. The agreement, which becomes effective in July 2024, provides Premier members with special pricing and terms for OssDsign's lead offering the OssDsign catalyst.
Bioventus provides an extensive line of surgical biologics for all bone grafting indications. Their products also extend to allografts and include franchise devices in autologous cell extraction bone marrow harvest, ultrasonic surgical tools for tissue specific applications. These solutions span patient conditions, types of surgeries and budgetary requirements.
In early 2024 Kuros Biosciences launched the MagnetOs family of products. The clearance covers the MagnetOs Granules and Easypack Putty for interbody use, plus based on a separate 510(k) filing last year, the MagnesOs granules as a standalone graft for posterolateral spine. In New Zealand, MagnetOs Granules and the recently launched novel putty format were granted regulatory approval by Medsafe in December 2020.
Orthobiologics are a group of advanced biotechnology products, which play in regenerative medicine categories. Novel biomaterials, growth factors and stem cell therapies along with advances in tissue engineering are broadening the field for treatment options leading to a remarkable expansion of orthobiologics market.
Increased Prevalence Of Orthopedic Injuries And Product Launches Drive The Market
The global market for orthobiologics is escalating rapidly due to the increasing population with musculoskeletal diseases. For example, osteoporosis causing more hip and spine fractures are major contributors like 6.8 million orthopedic injury cases annually in the U.S according to American Academy of Orthopedic Surgeons as an example.
key players in the orthobiologics market are introducing novel products which is translating into encouraging growth traction. The spectrum varies from allografts to bone growth factors and synthetic bone substitutes. For example, Royal Biologics gave its DMSO-free viable cellular bone allograft called MAGNUS in January 2020. Moreover, increasing inclination towards antibiotic-eluting bone void fillers in treatment of various bone disorders also favouring the growth of orthobiologics market. This is illustrated through the CE Mark approval of STIMULAN by biocomposites during April 2020 which includes use with certain antibiotic solutions (e.g. vancomycin, gentamicin and tobramycin) in bone void fillers for infected soft tissue and/or bone management applications and with the development of new orthobiologic products is anticipated to increase market growth in future.
For instance, Locate Bio is a new high flyer on the orthobiologics block and has achieved some major milestones in 2023. The company received FDA approval to designation for its LDGraft device in May 2023. This designates medication as "heal or critical" which allows faster approval of new drugs to treat serious diseases and anything generating irreversible suffering. In April 2024, they announced that, hit £9.2 million ($11.6m) in funding to further develop their tests and push towards getting them into clinics, with COVID-19 increasing industrial resonance as it claims the lives not just for elder but also young people across U.S.
High Costs, Regulatory Issues Preventing Growth
Although very promising, the market for orthobiologics is also plagued with several problems. Most importantly, the cost of developing, manufacturing and delivering these products is higher and tends to slow market penetration. Also, because the regulatory processes are so stringent (as they should be to ensure product safety and efficacy) bringing a new product to market can prove time-costly as well - in steps of FDA. All of these together make up an orthobiologics companies complex as well as competitive landscape.
Allograft
Bone morphogenetic protein (BMP)
Viscosupplementation
Synthetic bone substitutes
Stem cell therapy
Viscosupplementation dominated the orthobiologics market in 2023, accounting for over 40% of revenue. This segment is propelled by the surging osteoarthritis patient population, which is expected to increase by 132.2% from 1990 to 2020, reaching 595 million cases globally. Projections indicate further growth in osteoarthritis cases, particularly for knees, hands, and hips, by 74.9%, 48.6%, and 78.6%, respectively, by 2050. Hyaluronic acid injections, the primary method, contributes to orthobiologics market expansion due to their ease of use and good tolerance.
The stem cell therapy segment is poised for the fastest growth during the forecast period. Rising healthcare spending, an emphasis on personalized medicine, and advancements in biotechnology and regenerative medicine are creating a favorable environment for this segment's expansion. Innovative stem cell therapy techniques and products are driving market growth.
Do You Need any Customization Research on Orthobiologics Market - Enquire Now
Spinal fusion
Trauma repair
Reconstructive surgery
Spinal fusion led the orthobiologics market in 2023, with over 50% of share. This is driven by the escalating prevalence of spine disorders, with over 400,000 spinal fusion surgeries performed annually in the U.S. The use of bone morphogenetic proteins, demineralized bone matrices, autografts, and allografts, due to their efficacy in promoting bone stability and healing, is fueling segment growth. For instance, OssDsign AB, now focusing exclusively on orthobiologics, is concentrating on its nanosynthetic bone graft, OssDsign Catalyst, which boasts high-growth margins and is designed for spinal fusion procedures.
The reconstructive surgery segment is projected to experience substantial growth. An aging population, coupled with the rise in musculoskeletal disorders, is driving demand for reconstructive procedures. The surge in both surgical and non-surgical procedures performed by plastic surgeons, increasing by 11.2% in 2022 to reach 18.8 million and 14.9 million, respectively, underscores this factor. Orthobiologics are increasingly utilized in reconstructive surgeries to enhance bone healing, soft tissue repair, and joint function restoration.
Hospitals
Outpatient Facilities
Hospitals dominated over 60% of the orthobiologics market share in 2023. Their advanced infrastructure and comprehensive services make them well-equipped for utilizing these products.
A key driver for hospitals is the rising demand for minimally invasive procedures, which orthobiologics facilitate. These interventions leverage the body's natural healing processes, minimizing the need for extensive surgeries and long hospital stays. Additionally, hospitals integrate advanced imaging and surgical techniques, allowing for precise administration of orthobiologics, promoting tissue regeneration and swifter recovery.
Outpatient facilities are anticipated to experience significant growth due to the growing trend towards ambulatory care and same-day surgeries. This shift offers patients seeking minor orthopedic procedures or sports injury treatments a convenient and cost-effective option. For example, a Definitive Healthcare report revealed that Specialists One-Day Surgery Centers performed a notable 1.6% of all knee replacement procedures in 2022, highlighting the increasing role of outpatient facilities.
North America held the largest share of the global orthobiologics market in 2023, accounting for 46.2% of revenue. This dominance is attributed to advanced technologies, robust healthcare infrastructure, favorable reimbursement policies, and a supportive regulatory environment. The region's aging population, with a median age increasing to 0.2 years in 2022, further fuels market growth. The U.S. orthobiologics market is the primary growth driver within North America, representing nearly 90% of the regional market. A strong emphasis on research and technological innovation has led to a pipeline of advanced orthobiologic products. For example, Dr. Scott A. Rodeo from Hospital for Special Surgery received a USD 50,000 grant in July 2021 to research an injectable biologic for knee treatment.
The Europe orthobiologics market is the fastest growing region driven by an aging population grappling with an increased incidence of musculoskeletal disorders, demand for innovative treatment solutions like orthobiologics is on the rise. Additionally, the presence of a strong pharmaceutical and medical device industry within Europe fosters research and development in this field, further stimulating market expansion.
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Bone Biologics Corp., Medtronic PLC, Anika Therapeutics, Inc., DePuy Synthes, Arthrex, Inc., Zimmer Biomet, Globus Medical, Stryker Corporation, Orthofix, Inc., Bioventus LLC and others.
Isto Biologics and Advanced Biologics merged in October 2023 to create a combined force in the orthobiologics market. The merger integrated Advanced Biologics' proprietary products into Isto's Influx allograft portfolio. The companies had previously collaborated since 2020 on Isto's SPARC integrative bone matrix, which leveraged Advanced Biologics' tissue processing technology used in its OsseoGen allograft.
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.15 Bn |
| Market Size by 2032 | US$ 11.59 Bn |
| CAGR | CAGR of 5.55% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product • By Application (Spinal fusion, Trauma repair, Reconstructive surgery) • By End-use |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Bone Biologics Corp., Medtronic Plc, Anika Therapeutics, Inc., DePuy Synthes, Arthrex, Inc., Zimmer Biomet, Globus Medical, Stryker Corporation, Orthofix, Inc., Bioventus LLC and others. |
| Key Drivers | • Increased Prevalence Of Orthopedic Injuries And Product Launches Drive The Market |
| Market Restraints | • High Costs, Regulatory Issues Preventing Growth |
Ans: The Orthobiologics Market is to grow at 5.55% Over the Forecast Period 2024-2032.
Ans: The Orthobiologics Market is to Hit USD 11.59 Billion By 2032.
Ans: Bone Biologics Corp., Medtronic Plc, Anika Therapeutics, Inc., DePuy Synthes, Arthrex, Inc., Zimmer Biomet, Globus Medical, Stryker Corporation, Orthofix, Inc., Bioventus LLC and others.
Ans: The Orthobiologics Market size was valued at USD 7.15 Billion in 2023.
Ans: The stem cells that heal the wound after a bone fracture either produce new bone or new cartilage.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Orthobiologics Market Segmentation, By Product
7.1 Introduction
7.2 Demineralized Bone Matrix (DBM)
7.3 Allograft
7.4 Bone morphogenetic protein (BMP)
7.5 Viscosupplementation
7.6 Synthetic bone substitutes
7.7 Stem cell therapy
8. Orthobiologics Market Segmentation, By Application
8.1 Introduction
8.2 Spinal fusion
8.3 Trauma repair
8.4 Reconstructive surgery
9. Orthobiologics Market Segmentation, By End-use
9.1 Introduction
9.2 Hospitals
9.3 Outpatient Facilities
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 Trend Analysis
10.2.2 North America Orthobiologics Market by Country
10.2.3 North America Orthobiologics Market By Product
10.2.4 North America Orthobiologics Market By Application
10.2.5 North America Orthobiologics Market By End-use
10.2.6 USA
10.2.6.1 USA Orthobiologics Market By Product
10.2.6.2 USA Orthobiologics Market By Application
10.2.6.3 USA Orthobiologics Market By End-use
10.2.7 Canada
10.2.7.1 Canada Orthobiologics Market By Product
10.2.7.2 Canada Orthobiologics Market By Application
10.2.7.3 Canada Orthobiologics Market By End-use
10.2.8 Mexico
10.2.8.1 Mexico Orthobiologics Market By Product
10.2.8.2 Mexico Orthobiologics Market By Application
10.2.8.3 Mexico Orthobiologics Market By End-use
10.3 Europe
10.3.1 Trend Analysis
10.3.2 Eastern Europe
10.3.2.1 Eastern Europe Orthobiologics Market by Country
10.3.2.2 Eastern Europe Orthobiologics Market By Product
10.3.2.3 Eastern Europe Orthobiologics Market By Application
10.3.2.4 Eastern Europe Orthobiologics Market By End-use
10.3.2.5 Poland
10.3.2.5.1 Poland Orthobiologics Market By Product
10.3.2.5.2 Poland Orthobiologics Market By Application
10.3.2.5.3 Poland Orthobiologics Market By End-use
10.3.2.6 Romania
10.3.2.6.1 Romania Orthobiologics Market By Product
10.3.2.6.2 Romania Orthobiologics Market By Application
10.3.2.6.4 Romania Orthobiologics Market By End-use
10.3.2.7 Hungary
10.3.2.7.1 Hungary Orthobiologics Market By Product
10.3.2.7.2 Hungary Orthobiologics Market By Application
10.3.2.7.3 Hungary Orthobiologics Market By End-use
10.3.2.8 Turkey
10.3.2.8.1 Turkey Orthobiologics Market By Product
10.3.2.8.2 Turkey Orthobiologics Market By Application
10.3.2.8.3 Turkey Orthobiologics Market By End-use
10.3.2.9 Rest of Eastern Europe
10.3.2.9.1 Rest of Eastern Europe Orthobiologics Market By Product
10.3.2.9.2 Rest of Eastern Europe Orthobiologics Market By Application
10.3.2.9.3 Rest of Eastern Europe Orthobiologics Market By End-use
10.3.3 Western Europe
10.3.3.1 Western Europe Orthobiologics Market by Country
10.3.3.2 Western Europe Orthobiologics Market By Product
10.3.3.3 Western Europe Orthobiologics Market By Application
10.3.3.4 Western Europe Orthobiologics Market By End-use
10.3.3.5 Germany
10.3.3.5.1 Germany Orthobiologics Market By Product
10.3.3.5.2 Germany Orthobiologics Market By Application
10.3.3.5.3 Germany Orthobiologics Market By End-use
10.3.3.6 France
10.3.3.6.1 France Orthobiologics Market By Product
10.3.3.6.2 France Orthobiologics Market By Application
10.3.3.6.3 France Orthobiologics Market By End-use
10.3.3.7 UK
10.3.3.7.1 UK Orthobiologics Market By Product
10.3.3.7.2 UK Orthobiologics Market By Application
10.3.3.7.3 UK Orthobiologics Market By End-use
10.3.3.8 Italy
10.3.3.8.1 Italy Orthobiologics Market By Product
10.3.3.8.2 Italy Orthobiologics Market By Application
10.3.3.8.3 Italy Orthobiologics Market By End-use
10.3.3.9 Spain
10.3.3.9.1 Spain Orthobiologics Market By Product
10.3.3.9.2 Spain Orthobiologics Market By Application
10.3.3.9.3 Spain Orthobiologics Market By End-use
10.3.3.10 Netherlands
10.3.3.10.1 Netherlands Orthobiologics Market By Product
10.3.3.10.2 Netherlands Orthobiologics Market By Application
10.3.3.10.3 Netherlands Orthobiologics Market By End-use
10.3.3.11 Switzerland
10.3.3.11.1 Switzerland Orthobiologics Market By Product
10.3.3.11.2 Switzerland Orthobiologics Market By Application
10.3.3.11.3 Switzerland Orthobiologics Market By End-use
10.3.3.12 Austria
10.3.3.12.1 Austria Orthobiologics Market By Product
10.3.3.12.2 Austria Orthobiologics Market By Application
10.3.3.12.3 Austria Orthobiologics Market By End-use
10.3.3.13 Rest of Western Europe
10.3.3.13.1 Rest of Western Europe Orthobiologics Market By Product
10.3.3.13.2 Rest of Western Europe Orthobiologics Market By Application
10.3.3.13.3 Rest of Western Europe Orthobiologics Market By End-use
10.4 Asia-Pacific
10.4.1 Trend Analysis
10.4.2 Asia-Pacific Orthobiologics Market by Country
10.4.3 Asia-Pacific Orthobiologics Market By Product
10.4.4 Asia-Pacific Orthobiologics Market By Application
10.4.5 Asia-Pacific Orthobiologics Market By End-use
10.4.6 China
10.4.6.1 China Orthobiologics Market By Product
10.4.6.2 China Orthobiologics Market By Application
10.4.6.3 China Orthobiologics Market By End-use
10.4.7 India
10.4.7.1 India Orthobiologics Market By Product
10.4.7.2 India Orthobiologics Market By Application
10.4.7.3 India Orthobiologics Market By End-use
10.4.8 Japan
10.4.8.1 Japan Orthobiologics Market By Product
10.4.8.2 Japan Orthobiologics Market By Application
10.4.8.3 Japan Orthobiologics Market By End-use
10.4.9 South Korea
10.4.9.1 South Korea Orthobiologics Market By Product
10.4.9.2 South Korea Orthobiologics Market By Application
10.4.9.3 South Korea Orthobiologics Market By End-use
10.4.10 Vietnam
10.4.10.1 Vietnam Orthobiologics Market By Product
10.4.10.2 Vietnam Orthobiologics Market By Application
10.4.10.3 Vietnam Orthobiologics Market By End-use
10.4.11 Singapore
10.4.11.1 Singapore Orthobiologics Market By Product
10.4.11.2 Singapore Orthobiologics Market By Application
10.4.11.3 Singapore Orthobiologics Market By End-use
10.4.12 Australia
10.4.12.1 Australia Orthobiologics Market By Product
10.4.12.2 Australia Orthobiologics Market By Application
10.4.12.3 Australia Orthobiologics Market By End-use
10.4.13 Rest of Asia-Pacific
10.4.13.1 Rest of Asia-Pacific Orthobiologics Market By Product
10.4.13.2 Rest of Asia-Pacific Orthobiologics Market By Application
10.4.13.3 Rest of Asia-Pacific Orthobiologics Market By End-use
10.5 Middle East & Africa
10.5.1 Trend Analysis
10.5.2 Middle East
10.5.2.1 Middle East Orthobiologics Market by Country
10.5.2.2 Middle East Orthobiologics Market By Product
10.5.2.3 Middle East Orthobiologics Market By Application
10.5.2.4 Middle East Orthobiologics Market By End-use
10.5.2.5 UAE
10.5.2.5.1 UAE Orthobiologics Market By Product
10.5.2.5.2 UAE Orthobiologics Market By Application
10.5.2.5.3 UAE Orthobiologics Market By End-use
10.5.2.6 Egypt
10.5.2.6.1 Egypt Orthobiologics Market By Product
10.5.2.6.2 Egypt Orthobiologics Market By Application
10.5.2.6.3 Egypt Orthobiologics Market By End-use
10.5.2.7 Saudi Arabia
10.5.2.7.1 Saudi Arabia Orthobiologics Market By Product
10.5.2.7.2 Saudi Arabia Orthobiologics Market By Application
10.5.2.7.3 Saudi Arabia Orthobiologics Market By End-use
10.5.2.8 Qatar
10.5.2.8.1 Qatar Orthobiologics Market By Product
10.5.2.8.2 Qatar Orthobiologics Market By Application
10.5.2.8.3 Qatar Orthobiologics Market By End-use
10.5.2.9 Rest of Middle East
10.5.2.9.1 Rest of Middle East Orthobiologics Market By Product
10.5.2.9.2 Rest of Middle East Orthobiologics Market By Application
10.5.2.9.3 Rest of Middle East Orthobiologics Market By End-use
10.5.3 Africa
10.5.3.1 Africa Orthobiologics Market by Country
10.5.3.2 Africa Orthobiologics Market By Product
10.5.3.3 Africa Orthobiologics Market By Application
10.5.3.4 Africa Orthobiologics Market By End-use
10.5.3.5 Nigeria
10.5.3.5.1 Nigeria Orthobiologics Market By Product
10.5.3.5.2 Nigeria Orthobiologics Market By Application
10.5.3.5.3 Nigeria Orthobiologics Market By End-use
10.5.3.6 South Africa
10.5.3.6.1 South Africa Orthobiologics Market By Product
10.5.3.6.2 South Africa Orthobiologics Market By Application
10.5.3.6.3 South Africa Orthobiologics Market By End-use
10.5.3.7 Rest of Africa
10.5.3.7.1 Rest of Africa Orthobiologics Market By Product
10.5.3.7.2 Rest of Africa Orthobiologics Market By Application
10.5.3.7.3 Rest of Africa Orthobiologics Market By End-use
10.6 Latin America
10.6.1 Trend Analysis
10.6.2 Latin America Orthobiologics Market by country
10.6.3 Latin America Orthobiologics Market By Product
10.6.4 Latin America Orthobiologics Market By Application
10.6.5 Latin America Orthobiologics Market By End-use
10.6.6 Brazil
10.6.6.1 Brazil Orthobiologics Market By Product
10.6.6.2 Brazil Orthobiologics Market By Application
10.6.6.3 Brazil Orthobiologics Market By End-use
10.6.7 Argentina
10.6.7.1 Argentina Orthobiologics Market By Product
10.6.7.2 Argentina Orthobiologics Market By Application
10.6.7.3 Argentina Orthobiologics Market By End-use
10.6.8 Colombia
10.6.8.1 Colombia Orthobiologics Market By Product
10.6.8.2 Colombia Orthobiologics Market By Application
10.6.8.3 Colombia Orthobiologics Market By End-use
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Orthobiologics Market By Product
10.6.9.2 Rest of Latin America Orthobiologics Market By Application
10.6.9.3 Rest of Latin America Orthobiologics Market By End-use
11. Company Profiles
11.1 Bone Biologics Corp.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 The SNS View
11.2 Medtronic Plc
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 The SNS View
11.3 Anika Therapeutics, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 The SNS View
11.4 DePuy Synthes
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 The SNS View
11.5 Arthrex, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 The SNS View
11.6 Zimmer Biomet
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 The SNS View
11.7 Globus Medical
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 The SNS View
11.8 Stryker Corporation
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 The SNS View
11.9 Orthofix, Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 The SNS View
11.10 Bioventus LLC
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Vitrification Market Size, valued at USD 8.23 billion in 2023, is projected to reach USD 33.04 billion by 2032, growing at a CAGR of 16.75%.
The Weight Loss Devices Market Size was valued at USD 5.30 Billion in 2023 and is expected to reach USD 8.50 Billion by 2032 and grow at a CAGR of 6.60% over the forecast period 2024-2032.
The Artificial Hip Joint Market size was escalated to USD 7.66 billion by the end of 2023 and is projected to reach at USD 9.82 billion by 2031 with a growing healthy CAGR of 3.6% during the forecast period 2024-2031.
The Medical Nonwoven Disposable Market Size was valued at USD 25.0 billion in 2023 and is expected to reach USD 67.99 billion by 2031 and grow at a CAGR of 13.3% over the forecast period 2024-2031.
The Point of Care Lipid Test Market size was estimated USD 305.53 million in 2023 and is expected to reach USD 444.36 million by 2032 at a CAGR of 4.25% during the forecast period of 2024-2032.
The Neurovascular Devices Market Size was valued at USD 3.01 billion in 2023, and is expected to reach USD 4.81 billion by 2030, and grow at a CAGR of 6.05% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
